



# Coops: An aspirational legacy

Tony Kelleher | 24th September, 2018

A Legacy to Aspire to, 2018



## David A Cooper

AC, FAA, FAHMS,  
D.Sc, MD, FRACP, FRCPA





19<sup>th</sup> April 1949 -18<sup>th</sup> March 2018

A Legacy to Aspire to, 2018

UNSW


JOURNAL OF THE AUSTRALIAN MEDICAL ASSOCIATION  
June 11, 1985, 70th Year — Vol. 1, No. 12: 537-592

**MJA** THE ACQUIRED IMMUNE DEFICIENCY SYNDROME  
THE MEDICAL JOURNAL OF AUSTRALIA

Perhaps we've needed a situation like this to show us what we have known all along — depravity kills!

**The black plague of the eighties ...**



A Legacy to Aspire to, 2018

UNSW

## Clinically driven observations

The Lancet • Saturday 9 March 1985

### ACUTE AIDS RETROVIRUS INFECTION

#### Definition of a Clinical Illness Associated with Seroconversion

DAVID A. COOPER JULIAN GOLD  
PRUDENCE MACLEAN BASIL DONOVAN  
ROBERT FINLAYSON TIMOTHY G. BARNES  
HARRY M. MICHELMORE PETER BROOKE  
RONALD PENNY  
for the Sydney AIDS Study Group\*

*Lancet* 1999; **353**: 2093–99

Articles

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

Andrew Carr, Katherine Samaras, Anna Thorisdottir, Gilbert R Kaufmann, Donald J Chisholm, David A Cooper

## THE LANCET

Vol 340

Saturday 10 October 1992

No 8824

### Long-term symptomless HIV-1 infection in recipients of blood products from a single donor


JENNIFER LEARMONT BRETT TINDALL LOUISE EVANS  
ANTHONY CUNNINGHAM PHILLIP CUNNINGHAM JOHN WELLS  
RONALD PENNY JOHN KALDOR DAVID A. COOPER

*Lancet* 1998; **352**: 1881–83

Hypothesis

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance


Andrew Carr, Katherine Samaras, Donald J Chisholm, David A Cooper



## Global Reach and Global Impact

### Collaborations

- 650+ organisations  
in 43 countries on 6 continents



- **Therapeutics**  
ESPRIT & **INSIGHT**  
**TREAT ASIA**  
**Kirby Network**
- **Primary Infection**  
SAPS  
AIEDRP  
CASCADE  
SPARTAC
- **Prevention**  
HVDDT  
**EAVI**  
**EPIC**
- **Translational Science**  
**PROGRAM Grants x 4**

7

## Mentor



8



A Legacy to Aspire to, 2018



## Strategic trials: Impact on Therapeutic Guidelines

### The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 NOVEMBER 30, 2006 VOL. 355 NO. 22

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

INITIO Trial International Co-ordinating Committee\*

#### CD4+ Count-Guided Interruption of Antiretroviral Treatment

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group\*

#### Summary

Background Antiretroviral therapy has greatly reduced HIV mortality and morbidity. However, the best sequence of regimens and implications of initial regimens for long-term therapeutic success are not well defined.

Lancet 2006; 368: 107-18  
\*listed at end of paper

### The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 JANUARY 17, 2013 VOL. 368 NO. 3

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

ENCORE1 Study Group\*

#### Summary

Background The week 48 primary analysis of the ENCORE1 trial established the virological non-inferiority and safety of efavirenz 400 mg compared with the standard 600 mg dose, combined with zidovudine and zalcitabine, as first-line HIV therapy. This 96-week follow-up of the trial assesses the durability of efficacy and safety of this treatment over 96 weeks.

Lancet Infect Dis 2015; 15: 763-767  
Published Online April 23, 2015  
http://dx.doi.org/10.1016/S1473-3099(15)00606-5

#### Short-Course Antiretroviral Therapy in Primary HIV Infection

The SPARTAC Trial Investigators\*

### The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 AUGUST 27, 2015 VOL. 373 NO. 9

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

SECOND-LINE Study Group\*

#### Summary

Background Uncertainty exists about the best treatment for people with HIV-1 who have virological failure with first-line combination antiretroviral therapy of a non-nucleoside analogue (NNRTI) plus two nucleoside or nucleotide analogue reverse transcriptase inhibitors (NRTIs). We compared a second-line regimen combining two new classes of drug with a WHO-recommended regimen.

Lancet 2015; 385: 2093-99  
See Comment page 2162  
\*mentioned at end of paper

#### Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The INSIGHT START Study Group\*

A Legacy to Aspire to, 2018



## Advocacy



IAS Governing Council Meeting in Geneva, July 1998



A Legacy to Aspire to, 2018



## Partnerships




The HIV Netherlands Australia Thailand  
Research Collaboration

ศูนย์ประสานความร่วมมือระหว่างไทย ออสเตรเลีย เนเธอร์แลนด์ เพื่อการศึกษาวัยจี้ทางคลินิกด้านโรคเอดส์

1<sup>st</sup> HIV-Nat Retreat, 1998



Bangkok Symposium, 1997-2019



11

A Legacy to Aspire to, 2018



## Partnerships



**MARCH**


MYANMAR AUSTRALIA RESEARCH  
COLLABORATION FOR HEALTH



UM2, Yangon, 2017



Before Coops, 2017




After Coops, 2018

12

A Legacy to Aspire to, 2018



## Partnerships and Capacity Building



A Legacy to Aspire to, 2018



**Professor David Cooper, an inspirational leader, mentor and friend: much missed, always in our hearts.**



**“The story of HIV is a modern medical miracle. From despair and tragedy, we have moved into an era of chronic treatable illness, in just 30 years.”**  
**- David Cooper**